Lv1
56 积分 2024-09-19 加入
Claudin peptidomimetics modulate tissue barriers for enhanced drug delivery
6小时前
已完结
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
19天前
已完结
Modifying the blood–brain barrier by targeting claudin‐5: Safety and risks
20天前
已完结
Radiotherapy opens the blood–brain barrier and synergizes with anlotinib in treating glioblastoma
21天前
已完结
Local ablative therapy of oligoprogressive disease prolongs disease control in patients with EGFR-mutant NSCLC treated with first-line EGFR-TKI
25天前
已关闭
Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance
1个月前
已完结
Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer
1个月前
已完结
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
1个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
